Bone is a preferred site for breast cancer metastasis and leads to pathologic bone loss due to increased osteoclast-induced bone resorption. The homing of tumor cells to the bone depends on the support of the bone microenvironment in which the tumor cells prime the premetastatic niche. The colonization and growth of tumor cells then depend on adaptations in the invading tumor cells to take advantage of normal physiologic responses by mimicking bone marrow cells. This concerted effort by tumor cells leads to uncoupled bone remodeling in which the balance of osteoclast-driven bone resorption and osteoblast-driven bone deposition is lost. Breast cancer bone metastases often lead to osteolytic lesions due to hyperactive bone resorption. Release of growth factors from bone matrix during resorption then feeds a “vicious cycle” of bone destruction leading to many skeletal-related events. In addition to activity in bone, some of the factors released during bone resorption are also known to be involved in skeletal muscle regeneration and contraction. In this review, we discuss the mechanisms that lead to osteolytic breast cancer bone metastases and the potential for cancer-induced bone-muscle cross-talk leading to skeletal muscle weakness. Clin Cancer Res; 20(12); 3071–7. ©2014 AACR.

Bone metastases are common in patients with advanced malignancy. Primary tumors exhibit metastatic tropism to particular organs and the skeleton is a preferred site for breast cancer metastasis. Breast cancer that is metastatic to bone causes a significant imbalance in normal bone remodeling through perturbation of osteoclast-mediated bone resorption and osteoblast-mediated bone formation (1). Bone metastases are classified on the basis of radiographic appearance as either osteolytic or osteoblastic (osteosclerotic). Breast cancer is typically associated with osteolytic lesions, but most cases involve uncoupled components of both bone destruction and new bone formation. Bone metastases from breast cancer affect 65% to 80% of patients with advanced malignancy (2). Bone metastases cause severe bone pain and increased risk of pathologic fracture, hypercalcemia, and nerve compression syndromes that significantly reduce the quality of life (1). Perhaps most devastating is the fact that once the primary tumor has spread to the bone, it is incurable. The current standard of care for patients with bone loss due to osteolytic bone metastases includes antiresorptive therapy aimed at reducing skeletal-related events but is not curative with regard to tumor burden (1, 2).

A significant comorbidity of osteolytic bone metastases is muscle weakness and fatigue that is often associated with cancer cachexia. Cachexia is a common paraneoplastic syndrome that is characterized by severe wasting due to loss of both fat and lean body mass (3, 4). Although the age and chemotherapeutic treatment regimens of patients with advanced disease and bone metastases make it difficult to assess the true incidence of malignancy-induced muscle weakness (5), a clinical perspective suggests that many patients do experience severe muscle weakness and fatigue. Improving muscle function and mobility of patients with cancer would have a positive impact on adherence to treatment regimens and overall health (5). Therefore, a better understanding of the mechanism(s) of muscle weakness associated with bone metastases and cancer cachexia will lead to targeted therapeutics. Moreover, refocusing attention to determine muscle quality in addition to improving muscle mass will likely provide the most beneficial treatment options for this devastating complication of malignancy.

Molecular mechanisms of bone metastasis

The initiation and progression of bone metastasis are complex multistep processes. Tumor cells must detach from the primary tumor and enter the systemic circulation (intravasation), evade detection by the immune system, and adhere to capillaries in the bone marrow leading to extravasation into the bone marrow space (6). Tumor cells in the bone first form micrometastases that can either develop into overt metastatic lesions or lay dormant for long periods before reactivating in the bone microenvironment. In either case, it is believed that the invading tumor cells prime the bone microenvironment by enriching the premetastatic niche (local environment) for further colonization and growth of tumor cells (Fig. 1; refs. 2, 7–9).

Figure 1.

Premetastatic niche and bone homing. Modulation of the bone microenvironment by circulating breast cancer cells results in priming of the bone marrow as a premetastatic niche through tumor cell secretion of OPN, HPSE, and PTHrP. Colonization of the bone and recruitment of HSC occur by tumor cell expression of integrins (αvβ3), RANK, CXCR4, MMP-1, IL-11, and CTGF. CXCL12 (SDF-1) expression on osteoblasts facilitates homing of tumor cells to bone.

Figure 1.

Premetastatic niche and bone homing. Modulation of the bone microenvironment by circulating breast cancer cells results in priming of the bone marrow as a premetastatic niche through tumor cell secretion of OPN, HPSE, and PTHrP. Colonization of the bone and recruitment of HSC occur by tumor cell expression of integrins (αvβ3), RANK, CXCR4, MMP-1, IL-11, and CTGF. CXCL12 (SDF-1) expression on osteoblasts facilitates homing of tumor cells to bone.

Close modal

The hematopoietic system plays an important role in development of the premetastatic niche. The bone marrow may serve as a protective milieu for dormant tumor cells to resist chemotherapeutic attack, and tumor cells may use the same physiologic mechanisms as those used by hematopoietic stem cells (HSC) homing to bone (10, 11). In the premetastatic niche, the invading tumor cells prime the stroma by production of factors that elicit responses in cells of the bone microenvironment and make it conducive to tumor colonization and growth (2). In addition, bone resorption also regulates HSC homing (12). Factors derived from tumor cells include osteopontin (OPN), which promotes bone marrow cell migration and tumor cell proliferation (13, 14); heparanase (HPSE), which acts in the extracellular matrix to reduce heparin sulfate chain length leading to increased bone resorption (15); and parathyroid hormone-related protein (PTHrP), which promotes bone resorption (16) and may also enhance production of bone marrow chemokines such as C-C motif ligand 2 (17). Recently, it has also been shown that the sympathetic nervous system is also capable of stimulating stromal cells, thus promoting breast cancer bone metastasis (18).

Tumor cells invading the bone also express factors that facilitate further recruitment to the bone microenvironment, a process called osteotropism (19). αvβ3 integrin promotes adhesion of breast cancer cells in bone and is associated with bone metastasis (20). αvβ3 integrin also cooperates with bone sialoprotein and matrix metalloproteinase (MMP)-2 to promote tumor cell colonization in bone (21, 22). Receptor activator of NF-κB (RANK) mediates osteoclast-induced bone resorption and supports tumor cell colonization (23). The chemokine CXC ligand 12 [CXCL12; also known as stromal cell-derived factor 1 (SDF-1)] is a potent chemoattractant for HSCs and is highly expressed on osteoblasts and bone marrow stromal cells. Expression of its receptor, CXC receptor 4 (CXCR4), on cancer cells plays an important role in bringing tumor cells to bone (24). In addition, interactions between CXCL12 and CXCR4 in the bone microenvironment lead to an upregulation of αvβ3 integrin, facilitating additional cell adhesion. CXCR4 was identified as one of a set of proteins highly overexpressed in breast cancer cells (MDA-MB-231) of high bone metastatic potential by serial selection in vivo (10). Kang and colleagues also found that MMP-1, interleukin (IL)-11, and connective tissue growth factor (CTGF) were highly expressed in in vivo serially selected tumor cells that exhibited increased homing to bone compared with parental cells. IL-11 and MMP-1 stimulate bone resorption by increasing osteoblast production of RANK ligand (RANKL). Increased expression of MMP-1 and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS1) suppresses osteoprotegerin (OPG) expression in osteoblasts, which leads to osteoclast differentiation (25). CTGF stimulates osteoblast proliferation, which leads to further osteoclast activation and increased osteolysis (2).

Following osteotropism, the tumor cells adapt to the bone marrow space by expressing factors that allow growth in their new microenvironment. Osteolytic lesions are the most common type observed from breast cancers metastatic to bone. PTHrP secreted by breast cancer cells was the first characterized tumor-derived mediator of bone destruction (16). In mice without detectable circulating PTHrP or hypercalcemia, neutralizing antibodies to PTHrP blocked breast cancer bone metastases-associated bone loss and tumor growth. It was then shown that TGF-β in the bone microenvironment induced the expression of PTHrP by metastatic breast cancer cells that led to increased bone destruction (26). Breast cancer cells in bone also express COX-2, which supports the development and progression of bone metastases controlled by prostaglandin leading to bone resorption (27). The osteolytic factors IL-8 and IL-11 are also expressed by tumor cells in the bone microenvironment and directly support osteoclast maturation (28, 29). In addition to secreted factors, tumor cells express transcription factors that support growth in bone. The transcription factors, GLI2, runt-related transcription factor 2 (RUNX2), and hypoxia-inducible growth factor-1 α (HIF-1α) promote osteolysis. GLI2, part of the Hedgehog signaling network, induces PTHrP expression leading to bone destruction (30). RUNX2 regulates MMP-9 transcription leading to increased tumor cell invasion by breaking down the extracellular matrix (31). HIF-1α expression inhibits osteoblast differentiation and promotes osteoclastogenesis, thus supporting bone resorption and tumor growth (32, 33). Tumor cells also express Jagged1 (Jag1) that activates the Notch pathway, which activates osteoclast differentiation (34).

In the normal adult, setting bone is constantly remodeled to adjust for functional demands or to repair microfractures that occur as a part of normal activity. This process is driven by the coupled activity of osteoclasts that resorb mineralized matrix and osteoblasts that lay down new bone (35, 36). Ultimately, tumor cells in the bone microenvironment disrupt this normal physiologic process and skew balance toward either bone destruction or bone formation. In most breast cancers metastatic to bone, the tumor cells produce factors that directly or indirectly induce the formation of osteoclasts. In turn, bone resorption releases growth factors from bone matrix (e.g., TGF-β) that stimulate tumor growth and further osteolysis. This reciprocal interaction between breast cancer cells and the bone microenvironment results in a “vicious cycle” that increases both bone destruction and the tumor burden (Fig. 2; ref. 2).

Figure 2.

Vicious cycle of osteolytic bone metastasis. Osteolytic bone destruction due to dysregulation of normal bone remodeling is predominant in breast cancer metastasis. Breast cancer cells colonizing the bone secrete osteolytic factors: PTHrP, COX-2, and IL-11. Tumor cells also express transcription factors GLI2, RUNX2, and HIF-1α that promote osteolysis. Jag1 expressed on tumor cells activates osteoclast differentiation by inducing Notch signaling in preosteoclasts. Bone resorption releases TGF-β from the bone matrix, which enhances tumor cell proliferation and survival, thus feeding a vicious cycle leading to further bone destruction.

Figure 2.

Vicious cycle of osteolytic bone metastasis. Osteolytic bone destruction due to dysregulation of normal bone remodeling is predominant in breast cancer metastasis. Breast cancer cells colonizing the bone secrete osteolytic factors: PTHrP, COX-2, and IL-11. Tumor cells also express transcription factors GLI2, RUNX2, and HIF-1α that promote osteolysis. Jag1 expressed on tumor cells activates osteoclast differentiation by inducing Notch signaling in preosteoclasts. Bone resorption releases TGF-β from the bone matrix, which enhances tumor cell proliferation and survival, thus feeding a vicious cycle leading to further bone destruction.

Close modal

Preclinical data suggest that reducing bone resorption prevents the development of bone metastases. Osteoclast inhibitors are useful agents to slow or reverse bone loss (2), whereas antiresorptive therapy (bisphosphonates), OPG, and other RANKL antagonists reduce growth of bone metastases (37, 38). TGF-β antagonism is another mechanism for reducing tumor growth in bone. TGF-β is abundant in the mineralized bone matrix and is released from the matrix during osteoclastic bone resorption (39). Blocking the TGF-β pathway reduces bone metastasis and tumor burden (40–43). Blocking bone resorption, especially through modulating TGF-β signaling, offers a promising area for therapeutic intervention in bone metastasis and potentially its comorbidities.

Muscle dysfunction associated with breast cancer bone metastasis

Muscle and bone anabolism are tightly coupled during growth and development. Conversely, muscle and bone catabolism occur during aging. Yet the cellular and molecular mechanisms linking these two tissues are not well understood.

Muscle is known to secrete many factors capable of affecting other tissues. These factors, collectively termed myokines, include the bone active molecules insulin-like growth factor-I (IGF-I), fibroblast growth factor (FGF)-2, myostatin (also called growth and differentiation factor; GDF-8), and IL-6 (44). Our current understanding of bone and muscle cross-talk seems to show a predominant role of signaling in the direction of muscle to bone. Yet bone-derived factors are also known to modulate muscle. For example, Indian hedgehog promotes myoblast survival and myogenesis in both mouse and chick embryos (45) thus indicating bidirectional bone–muscle cross-talk. It seems likely that in cases of abnormal physiology, such as osteolytic bone metastases, the signals are co-opted and lead to a shift in the homeostatic signaling balance (Fig. 3).

Figure 3.

Bone–muscle cross-talk. Bone and muscle are physically and functionally tightly coupled. IGF-I, FGF-2, myostatin, and IL-6 are factors released from muscle that have functions in muscle as well as bone. These factors have been collectively termed myokines. Likewise, activin A, TGF-β, IGF-I, and BMP-2 released from bone affect bone as well as muscle, and thus we have called these osteokines. During osteolytic bone resorption due to breast cancer, bone metastasis osteokines are released and may be responsible for systemic skeletal muscle weakness. In certain settings, tumor-derived factors could also lead to modulation of muscle activity (dotted line).

Figure 3.

Bone–muscle cross-talk. Bone and muscle are physically and functionally tightly coupled. IGF-I, FGF-2, myostatin, and IL-6 are factors released from muscle that have functions in muscle as well as bone. These factors have been collectively termed myokines. Likewise, activin A, TGF-β, IGF-I, and BMP-2 released from bone affect bone as well as muscle, and thus we have called these osteokines. During osteolytic bone resorption due to breast cancer, bone metastasis osteokines are released and may be responsible for systemic skeletal muscle weakness. In certain settings, tumor-derived factors could also lead to modulation of muscle activity (dotted line).

Close modal

Data from our laboratory using a preclinical model of breast cancer bone metastases (MDA-MB-231 cells) show significant reduction in forelimb grip strength and ex vivo maximum specific force generation of the extensor digitorum longus (EDL) muscle that cannot be explained by reduction in muscle mass. Ex vivo specific force calculations compensate for differences in size and weight of individual muscles. Further muscle dysfunction is systemic and dependent on tumor-induced osteolytic bone resorption without tumor cell involvement in the muscle. Primary MDA-MB-231 tumors (mammary fat pad injection site) do not elicit muscle dysfunction (46). Our investigation into muscle function in mice with breast cancer bone metastases was borne out of the observation that these mice develop cachexia with advancing bone destruction. Cancer cachexia is one of the most common paraneoplastic conditions in advanced malignancy, occurring in approximately 80% of patients. There is no effective treatment for cancer cachexia, and it has been estimated to be responsible for 20% of cancer-related deaths (3, 47). However, there is a large heterogeneity in clinical presentation of cachexia that can vary according to tumor type, site, and individual patient factors. In fact, the true incidence of cancer cachexia is likely greatly underestimated (5).

Many well-established models of cancer cachexia have used reduction of muscle size to imply muscle dysfunction. However, this does not take into account the loss of muscle quality. Our laboratory has shown that mice with bone metastases exhibited a primary defect (in addition to loss of muscle weight) that is independent of cachexia, although mechanisms of cancer cachexia may also be at work (48). In a mouse model of multiple myeloma that leads to osteolytic bone lesions but without measurable cachexia, we observed systemic muscle dysfunction (49). In both of these mouse models of osteolytic bone loss, the severity of muscle dysfunction correlated with an increase in bone destruction.

The salient question therefore is what factor(s) derived from bone matrix during resorption is capable of inducing systemic muscle dysfunction? Bone matrix is a rich storehouse of growth factors that have known effects on muscle, such as activin A, TGF-β, IGF-I, and bone morphogenic protein 2 (BMP-2; refs. 50, 51). It is useful to begin by considering these as potentiators of muscle dysfunction due to bone destruction.

The high-affinity activin type 2 receptor, ActRIIB, mediates signaling of a small group of TGF-β family members (activin A, myostatin, GDF-11) and is important in regulating muscle mass (52). Pharmacologic blockade of ActRIIB prevents muscle wasting, induces muscle satellite cell mobilization and differentiation, and significantly prolongs survival in murine models of cachexia (53). In addition, blockade of ActRIIB dramatically improves muscle function in a Duchenne muscular dystrophy model (mdx mice; ref. 54). However, in these studies it is not possible to determine whether the effect is due to blocking activin A, myostatin, or GDF-11 signaling due to receptor usage overlap. Myostatin signaling antagonism has been investigated as a way to improve muscle wasting due to cachexia because myostatin is a potent inhibitor of skeletal muscle differentiation and growth (55). Activin A has also been shown to function with myostatin to reduce muscle size (56). GDF-11 shares 90% sequence homology with myostatin and in skeletal muscle inhibits myoblast differentiation (57), suggesting that GDF-11 may act in a very similar manner as myostatin.

TGF-β is a potent regulator of wound healing in muscle, and persistent exposure leads to altered extracellular matrix architecture and formation of fibrotic tissue in muscle (58). Increased TGF-β signaling in muscle also inhibits satellite cell activation and impairs myocyte differentiation (59, 60). Increased TGF-β signaling is also associated with skeletal muscle dysfunction in many of the muscular dystrophies (61, 62). In a direct assessment of the effect of TGF-β on muscle function, the contractile properties of the EDL muscle were examined from limbs exposed to recombinant TGF-β. Muscle function from limbs receiving TGF-β treatment exhibited a significant reduction in specific force (63). These experiments suggest that TGF-β is a capable factor in reducing muscle function independent of changes in muscle mass.

In contrast with the negative effects possible from activin A, myostatin, and TGF-β signaling in muscle, IGF-I and BMP-2 signaling results in muscle hypertrophy (58, 64, 65). IGF-I is a major regulator of muscle mass due to its effect on myogenic cell proliferation and differentiation (66). Likewise, BMP signaling leads to muscle hypertrophy, but, interestingly, specific force (corrected for muscle mass) is significantly lower when BMP signaling is constitutively activated (64). This result demonstrates the importance of interpreting muscle-specific function, not merely muscle mass, in murine models of skeletal muscle weakness.

In addition to factors released from bone matrix during osteoclast-driven resorption, other factors present in patients with malignancy involving bone may play important roles in muscle weakness. Serum vitamin D levels are low among patients with breast cancer with either osteoporosis or metastatic bone disease who are receiving bisphosphonate therapy (67). Vitamin D deficiency has been studied in rodent models using vitamin D receptor knockout (VDRKO) mice. Functional muscle tests in VDRKO mice exhibited an increase in sinking episodes in a forced swim test, reduced “time on” in a rotarod test (68, 69), and reduced time before falling from a vertical screen test (70). These results indicate an overall defect in motor performance in mice lacking proper vitamin D metabolism. In human studies, rickets and osteomalacia are associated with muscle weakness. In addition to general weakness, more specific muscle deficits are also commonly reported, including reduced timed up and go, 6-minute walk, stair climbing, and object lifting (71, 72). It should be noted that myopathies reported with vitamin D deficiency might also involve calcium and phosphate deficiencies, thus complicating the assessment of individual factors. FGF-23 neutralizing antibody, which increases serum phosphate and vitamin D levels, has been shown to improve murine grip strength in a model of rickets/osteomalacia (X-linked hypophosphatemic rickets/osteomalacia), suggesting that vitamin D levels could influence muscle function (73).

microRNA (miRNA) profiling of tumors has identified signatures associated with diagnosis and progression. Human miRNA Let-7 was recently shown to be elevated in serum of mice harboring breast cancer bone metastases (74). miRNA Let-7 is also elevated in serum of elderly patients with muscle weakness and has been suggested to reduce regenerative capacity in aging (75).

Another intriguing possibility is the role of the sympathetic nervous system in muscle weakness due to bone metastases. The sympathetic nervous system modulates skeletal muscle metabolism, ion transport, and contractility. Recent evidence has shown that the sympathetic nervous system is capable of promoting breast cancer bone metastasis through stimulation of marrow stromal cells (18), yet a connection to muscle weakness has not been investigated.

Bone and muscle functions are tightly coupled in normal physiology. Recent studies have focused on muscle as an endocrine organ with a predominant role over bone in bone–muscle cross-talk. Osteolytic bone metastases from breast cancer represent a severe divergence from normal bone physiology by tipping the balance of remodeling. Bone is a rich storehouse of growth factors that have activity in bone (as a part of normal remodeling) and in other organs, including muscle. It is therefore possible that during hyperactive bone resorption, bone might have a predominant role over muscle in bone–muscle cross-talk and become a source of “osteokines” that affect muscle function. Likewise, factors released from muscle may play an important role in bone metabolism that could further exacerbate the role of bone in muscle dysfunction. Identification and characterization of such factors would provide new possibilities for therapeutic intervention in muscle weakness associated with malignancy and perhaps cancer cachexia.

T.A. Guise reports receiving commercial research grants from AstraZeneca and Exelexis, is a consultant/advisory board member for Novartis, and has provided expert testimony on bisphosphonates and osteonecrosis of the jaw for Novartis. No potential conflicts of interest were disclosed by the other author.

This work was supported by NIH grants (U01CA143057 from the NCI Tumor Microenvironment Network; R01CA69158), the Susan G. Komen Foundation, the Indiana Economic Development Grant, the Jerry W. and Peggy S. Throgmartin Endowment of the Indiana University (IU) Simon Cancer Center, the IU Simon Cancer Center Breast Cancer Program, and a generous donation from the Withycombe family (to T.A. Guise).

1.
Roodman
GD
. 
Mechanisms of bone metastasis
.
N Engl J Med
2004
;
350
:
1655
64
.
2.
Weilbaecher
KN
,
Guise
TA
,
McCauley
LK
. 
Cancer to bone: a fatal attraction
.
Nat Rev Cancer
2011
;
11
:
411
25
.
3.
Fearon
KC
,
Glass
DJ
,
Guttridge
DC
. 
Cancer cachexia: mediators, signaling, and metabolic pathways
.
Cell Metab
2012
;
16
:
153
66
.
4.
Tisdale
MJ
. 
Mechanisms of cancer cachexia
.
Physiol Rev
2009
;
89
:
381
410
.
5.
Fox
KM
,
Brooks
JM
,
Gandra
SR
,
Markus
R
,
Chiou
CF
. 
Estimation of Cachexia among Cancer Patients Based on Four Definitions
.
Can J Oncol
2009
;
2009
:
693458
.
6.
Valastyan
S
,
Weinberg
RA
. 
Tumor metastasis: molecular insights and evolving paradigms
.
Cell
2011
;
147
:
275
92
.
7.
Lu
X
,
Mu
E
,
Wei
Y
,
Riethdorf
S
,
Yang
Q
,
Yuan
M
, et al
VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha4beta1-positive osteoclast progenitors
.
Cancer cell
2011
;
20
:
701
14
.
8.
Luzzi
KJ
,
MacDonald
IC
,
Schmidt
EE
,
Kerkvliet
N
,
Morris
VL
,
Chambers
AF
, et al
Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases
.
Am J Pathol
1998
;
153
:
865
73
.
9.
Watson
MA
,
Ylagan
LR
,
Trinkaus
KM
,
Gillanders
WE
,
Naughton
MJ
,
Weilbaecher
KN
, et al
Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients
.
Clin Cancer Res
2007
;
13
:
5001
9
.
10.
Kang
Y
,
Siegel
PM
,
Shu
W
,
Drobnjak
M
,
Kakonen
SM
,
Cordon-Cardo
C
, et al
A multigenic program mediating breast cancer metastasis to bone
.
Cancer cell
2003
;
3
:
537
49
.
11.
Yoneda
T
. 
Cellular and molecular basis of preferential metastasis of breast cancer to bone
.
J Orthop Sci
2000
;
5
:
75
81
.
12.
Kollet
O
,
Dar
A
,
Shivtiel
S
,
Kalinkovich
A
,
Lapid
K
,
Sztainberg
Y
, et al
Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells
.
Nat Med
2006
;
12
:
657
64
.
13.
Anborgh
PH
,
Mutrie
JC
,
Tuck
AB
,
Chambers
AF
. 
Role of the metastasis-promoting protein osteopontin in the tumour microenvironment
.
J Cell Mol Med
2010
;
14
:
2037
44
.
14.
McAllister
SS
,
Gifford
AM
,
Greiner
AL
,
Kelleher
SP
,
Saelzler
MP
,
Ince
TA
, et al
Systemic endocrine instigation of indolent tumor growth requires osteopontin
.
Cell
2008
;
133
:
994
1005
.
15.
Kelly
T
,
Suva
LJ
,
Huang
Y
,
Macleod
V
,
Miao
HQ
,
Walker
RC
, et al
Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases
.
Cancer Res
2005
;
65
:
5778
84
.
16.
Guise
TA
,
Yin
JJ
,
Taylor
SD
,
Kumagai
Y
,
Dallas
M
,
Boyce
BF
, et al
Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis
.
J Clin Invest
1996
;
98
:
1544
9
.
17.
Li
X
,
Loberg
R
,
Liao
J
,
Ying
C
,
Snyder
LA
,
Pienta
KJ
, et al
A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone
.
Cancer Res
2009
;
69
:
1685
92
.
18.
Campbell
JP
,
Karolak
MR
,
Ma
Y
,
Perrien
DS
,
Masood-Campbell
SK
,
Penner
NL
, et al
Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice
.
PLoS Biol
2012
;
10
:
e1001363
.
19.
Clezardin
P
,
Teti
A
. 
Bone metastasis: pathogenesis and therapeutic implications
.
Clin Exp Metastasis
2007
;
24
:
599
608
.
20.
Zhao
Y
,
Bachelier
R
,
Treilleux
I
,
Pujuguet
P
,
Peyruchaud
O
,
Baron
R
, et al
Tumor alphavbeta3 integrin is a therapeutic target for breast cancer bone metastases
.
Cancer Res
2007
;
67
:
5821
30
.
21.
Karadag
A
,
Ogbureke
KU
,
Fedarko
NS
,
Fisher
LW
. 
Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion
.
J Natl Cancer Inst
2004
;
96
:
956
65
.
22.
Waltregny
D
,
Bellahcene
A
,
de Leval
X
,
Florkin
B
,
Weidle
U
,
Castronovo
V
. 
Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers
.
J Bone Miner Res
2000
;
15
:
834
43
.
23.
Jones
DH
,
Nakashima
T
,
Sanchez
OH
,
Kozieradzki
I
,
Komarova
SV
,
Sarosi
I
, et al
Regulation of cancer cell migration and bone metastasis by RANKL
.
Nature
2006
;
440
:
692
6
.
24.
Liang
Z
,
Wu
T
,
Lou
H
,
Yu
X
,
Taichman
RS
,
Lau
SK
, et al
Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4
.
Cancer Res
2004
;
64
:
4302
8
.
25.
Lu
X
,
Wang
Q
,
Hu
G
,
Van Poznak
C
,
Fleisher
M
,
Reiss
M
, et al
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis
.
Genes Dev
2009
;
23
:
1882
94
.
26.
Yin
JJ
,
Selander
K
,
Chirgwin
JM
,
Dallas
M
,
Grubbs
BG
,
Wieser
R
, et al
TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development
.
J Clin Invest
1999
;
103
:
197
206
.
27.
Singh
B
,
Berry
JA
,
Shoher
A
,
Ayers
GD
,
Wei
C
,
Lucci
A
. 
COX-2 involvement in breast cancer metastasis to bone
.
Oncogene
2007
;
26
:
3789
96
.
28.
Zhang
Y
,
Fujita
N
,
Oh-hara
T
,
Morinaga
Y
,
Nakagawa
T
,
Yamada
M
, et al
Production of interleukin-11 in bone-derived endothelial cells and its role in the formation of osteolytic bone metastasis
.
Oncogene
1998
;
16
:
693
703
.
29.
Bendre
MS
,
Montague
DC
,
Peery
T
,
Akel
NS
,
Gaddy
D
,
Suva
LJ
. 
Interleukin-8 stimulation of osteoclastogenesis and bone resorption is a mechanism for the increased osteolysis of metastatic bone disease
.
Bone
2003
;
33
:
28
37
.
30.
Sterling
JA
,
Oyajobi
BO
,
Grubbs
B
,
Padalecki
SS
,
Munoz
SA
,
Gupta
A
, et al
The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells
.
Cancer Res
2006
;
66
:
7548
53
.
31.
Pratap
J
,
Javed
A
,
Languino
LR
,
van Wijnen
AJ
,
Stein
JL
,
Stein
GS
, et al
The Runx2 osteogenic transcription factor regulates matrix metalloproteinase 9 in bone metastatic cancer cells and controls cell invasion
.
Mol Cell Biol
2005
;
25
:
8581
91
.
32.
Dunn
LK
,
Mohammad
KS
,
Fournier
PG
,
McKenna
CR
,
Davis
HW
,
Niewolna
M
, et al
Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment
.
PloS one
2009
;
4
:
e6896
.
33.
Hiraga
T
,
Kizaka-Kondoh
S
,
Hirota
K
,
Hiraoka
M
,
Yoneda
T
. 
Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer
.
Cancer Res
2007
;
67
:
4157
63
.
34.
Sethi
N
,
Dai
X
,
Winter
CG
,
Kang
Y
. 
Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells
.
Cancer cell
2011
;
19
:
192
205
.
35.
Raggatt
LJ
,
Partridge
NC
. 
Cellular and molecular mechanisms of bone remodeling
.
J Biol Chem
2010
;
285
:
25103
8
.
36.
Allen
MR
,
Burr
DB
. 
Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: what we think we know and what we know that we don't know
.
Bone
2011
;
49
:
56
65
.
37.
Boissier
S
,
Ferreras
M
,
Peyruchaud
O
,
Magnetto
S
,
Ebetino
FH
,
Colombel
M
, et al
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases
.
Cancer Res
2000
;
60
:
2949
54
.
38.
Croucher
PI
,
Shipman
CM
,
Lippitt
J
,
Perry
M
,
Asosingh
K
,
Hijzen
A
, et al
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma
.
Blood
2001
;
98
:
3534
40
.
39.
Korpal
M
,
Yan
J
,
Lu
X
,
Xu
S
,
Lerit
DA
,
Kang
Y
. 
Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis
.
Nat Med
2009
;
15
:
960
6
.
40.
Biswas
S
,
Nyman
JS
,
Alvarez
J
,
Chakrabarti
A
,
Ayres
A
,
Sterling
J
, et al
Anti-transforming growth factor ss antibody treatment rescues bone loss and prevents breast cancer metastasis to bone
.
PloS one
2011
;
6
:
e27090
.
41.
Buijs
JT
,
Stayrook
KR
,
Guise
TA
. 
The role of TGF-beta in bone metastasis: novel therapeutic perspectives
.
BoneKEy Rep
2012
;
1
:
96
.
42.
Mohammad
KS
,
Chen
CG
,
Balooch
G
,
Stebbins
E
,
McKenna
CR
,
Davis
H
, et al
Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone
.
PloS one
2009
;
4
:
e5275
.
43.
Wright
LE
,
Frye
JB
,
Lukefahr
AL
,
Timmermann
BN
,
Mohammad
KS
,
Guise
TA
, et al
Curcuminoids block TGF-beta signaling in human breast cancer cells and limit osteolysis in a murine model of breast cancer bone metastasis
.
J Nat Prod
2013
;
76
:
316
21
.
44.
DiGirolamo
DJ
,
Kiel
DP
,
Esser
KA
. 
Bone and skeletal muscle: neighbors with close ties
.
J Bone Miner Res
2013
;
28
:
1509
18
.
45.
Bren-Mattison
Y
,
Hausburg
M
,
Olwin
BB
. 
Growth of limb muscle is dependent on skeletal-derived Indian hedgehog
.
Dev Biol
2011
;
356
:
486
95
.
46.
Waning
DL
,
Mohammad
KS
,
Andersson
DC
,
John
SK
,
Rieken
S
,
Xie
W
, et al
Role of the tumor-bone microenvironment in muscle weakness and cachexia. Cancer-Induced Bone Disease
.
Miami, FL
:
IBMS
; 
2013
.
47.
Fearon
K
,
Strasser
F
,
Anker
SD
,
Bosaeus
I
,
Bruera
E
,
Fainsinger
RL
, et al
Definition and classification of cancer cachexia: an international consensus
.
lancet Oncol
2011
;
12
:
489
95
.
48.
Fearon
K
,
Arends
J
,
Baracos
V
. 
Understanding the mechanisms and treatment options in cancer cachexia
.
Nat Rev Clin Oncol
2013
;
10
:
90
9
.
49.
Waning
DL
,
Mohammad
KS
,
Reiken
S
,
Marks
AR
,
Roodman
GD
,
Guise
TA
. 
Muscle weakness is associated with osteolysis in multiple myeloma. Cancer-Induced Bone Disease
.
Miami, FL
:
IBMS
; 
2013
.
50.
Sakai
R
,
Eto
Y
. 
Involvement of activin in the regulation of bone metabolism
.
Mol Cell Endocrinol
2001
;
180
:
183
8
.
51.
Wildemann
B
,
Kadow-Romacker
A
,
Haas
NP
,
Schmidmaier
G
. 
Quantification of various growth factors in different demineralized bone matrix preparations
.
J Biomed Mater Res A
2007
;
81
:
437
42
52.
Lee
SJ
,
Reed
LA
,
Davies
MV
,
Girgenrath
S
,
Goad
ME
,
Tomkinson
KN
, et al
Regulation of muscle growth by multiple ligands signaling through activin type II receptors
.
Proc Natl Acad Sci U S A
2005
;
102
:
18117
22
.
53.
Zhou
X
,
Wang
JL
,
Lu
J
,
Song
Y
,
Kwak
KS
,
Jiao
Q
, et al
Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival
.
Cell
2010
;
142
:
531
43
.
54.
Pistilli
EE
,
Bogdanovich
S
,
Goncalves
MD
,
Ahima
RS
,
Lachey
J
,
Seehra
J
, et al
Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy
.
Am J Pathol
2011
;
178
:
1287
97
.
55.
Zimmers
TA
,
Davies
MV
,
Koniaris
LG
,
Haynes
P
,
Esquela
AF
,
Tomkinson
KN
, et al
Induction of cachexia in mice by systemically administered myostatin
.
Science
2002
;
296
:
1486
8
.
56.
Lee
SJ
,
Lee
YS
,
Zimmers
TA
,
Soleimani
A
,
Matzuk
MM
,
Tsuchida
K
, et al
Regulation of muscle mass by follistatin and activins
.
Mol Endocrinol
2010
;
24
:
1998
2008
.
57.
Jeanplong
F
,
Falconer
SJ
,
Thomas
M
,
Matthews
KG
,
Oldham
AM
,
Watson
T
, et al
Growth and differentiation factor-11 is developmentally regulated in skeletal muscle and inhibits myoblast differentiation
.
Open Int J Mol Integr Physiol
2012
;
2
:
127
38
.
58.
Serrano
AL
,
Munoz-Canoves
P
. 
Regulation and dysregulation of fibrosis in skeletal muscle
.
Exp Cell Res
2010
;
316
:
3050
8
.
59.
Allen
RE
,
Boxhorn
LK
. 
Inhibition of skeletal muscle satellite cell differentiation by transforming growth factor-beta
.
J Cell Physiol
1987
;
133
:
567
72
.
60.
Allen
RE
,
Boxhorn
LK
. 
Regulation of skeletal muscle satellite cell proliferation and differentiation by transforming growth factor-beta, insulin-like growth factor I, and fibroblast growth factor
.
J Cell Physiol
1989
;
138
:
311
5
.
61.
Chen
YW
,
Nagaraju
K
,
Bakay
M
,
McIntyre
O
,
Rawat
R
,
Shi
R
, et al
Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy
.
Neurology
2005
;
65
:
826
34
.
62.
Kollias
HD
,
McDermott
JC
. 
Transforming growth factor-beta and myostatin signaling in skeletal muscle
.
J Appl Physiol
2008
;
104
:
579
87
.
63.
Mendias
CL
,
Gumucio
JP
,
Davis
ME
,
Bromley
CW
,
Davis
CS
,
Brooks
SV
. 
Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis
.
Muscle Nerve
2012
;
45
:
55
9
.
64.
Sartori
R
,
Schirwis
E
,
Blaauw
B
,
Bortolanza
S
,
Zhao
J
,
Enzo
E
, et al
BMP signaling controls muscle mass
.
Nat Genet
2013
;
45
:
1309
18
.
65.
Schiaffino
S
,
Mammucari
C
. 
Regulation of skeletal muscle growth by the IGF1-Akt/PKB pathway: insights from genetic models
.
Skeletal muscle
2011
;
1
:
4
.
66.
Florini
JR
,
Ewton
DZ
,
Coolican
SA
. 
Growth hormone and the insulin-like growth factor system in myogenesis
.
Endocr Rev
1996
;
17
:
481
517
.
67.
Wang-Gillam
A
,
Miles
DA
,
Hutchins
LF
. 
Evaluation of vitamin D deficiency in breast cancer patients on bisphosphonates
.
Oncologist
2008
;
13
:
821
7
.
68.
Burne
TH
,
Johnston
AN
,
McGrath
JJ
,
Mackay-Sim
A
. 
Swimming behaviour and post-swimming activity in Vitamin D receptor knockout mice
.
Brain Res Bull
2006
;
69
:
74
8
.
69.
Minasyan
A
,
Keisala
T
,
Zou
J
,
Zhang
Y
,
Toppila
E
,
Syvala
H
, et al
Vestibular dysfunction in vitamin D receptor mutant mice
.
J Steroid Biochem Mol Biol
2009
;
114
:
161
6
.
70.
Kalueff
AV
,
Lou
YR
,
Laaksi
I
,
Tuohimaa
P
. 
Impaired motor performance in mice lacking neurosteroid vitamin D receptors
.
Brain Res Bull
2004
;
64
:
25
9
.
71.
Russell
JA
. 
Osteomalacic myopathy
.
Muscle Nerve
1994
;
17
:
578
80
.
72.
Schott
GD
,
Wills
MR
. 
Muscle weakness in osteomalacia
.
Lancet
1976
;
1
:
626
9
.
73.
Aono
Y
,
Hasegawa
H
,
Yamazaki
Y
,
Shimada
T
,
Fujita
T
,
Yamashita
T
, et al
Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice
.
J Bone Miner Res
2011
;
26
:
803
10
.
74.
Ell
B
,
Mercatali
L
,
Ibrahim
T
,
Campbell
N
,
Schwarzenbach
H
,
Pantel
K
, et al
Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis
.
Cancer cell
2013
;
24
:
542
56
.
75.
Drummond
MJ
,
McCarthy
JJ
,
Sinha
M
,
Spratt
HM
,
Volpi
E
,
Esser
KA
, et al
Aging and microRNA expression in human skeletal muscle: a microarray and bioinformatics analysis
.
Physiol Genomics
2011
;
43
:
595
603
.